3 results
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Primary• To assess the effects of RVT-101 versus placebo on global function as measured by the Clinician*s Interview-Based Impression of Change Plus Caregiver Input (CIBIC+) after 24 weeks of treatment• To assess the effects of RVT-101 versus…
The objective of this randomized noninferiority trial is to determine whether INTELLiVENT*ASV with sidestream capnography is noninferior to INTELLiVENT*ASV with mainstream capnography with regard to the percentage of breaths in a broadly accepted…